Skip to main content
SpringerLink
Log in

Sildenafil is more cost effective than bosentan for the treatment of pulmonary hypertension,

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Harnett J, Van Engen A, Schoeman O.Economic evaluation of oral therapies for pulmonary arterial hypertension. Value in Health 9: 124 (plus poster) abstr. PCV18, No. 3, May-Jun 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sildenafil is more cost effective than bosentan for the treatment of pulmonary hypertension,. Pharmacoecon. Outcomes News 508, 3 (2006). https://doi.org/10.2165/00151234-200605080-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605080-00008

Keywords

Search

Navigation